Navigation Links
Biopharm Insight’s Respiratory Disease Report Highlights Key Drugs Coming Up for Approval or in Late-Stage Development
Date:11/6/2013

Norwood, MA (PRWEB) November 06, 2013

BioPharm Insight’s Respiratory Disease Report covers key drugs in development in this competitive therapeutic sector. The report is based on primary research and interviews conducted with numerous physicians, investigators and key opinion leaders at the recent European Respiratory Society Annual Congress 2013 in Barcelona, Spain.

In discussing the Respiratory Disease Report, Kirsty Barnes, Biopharm Insight’s Editor EMEA, said, “The report is another example of why decision makers in pharmaceutical R&D or the investment side of drug development rely on BioPharm Insight’s independent investigative journalism, market analytics and key industry contacts to gain competitive insight.”

Some highlights and key takeaways from the report:

  •     Competitive landscape of LABA/LAMA combinations in development to treat COPD
  •     Novartis'combination drug Ultibro Breezhaler for chronic obstructive pulmonary disease (COPD) and US market outlook
  •     Forest and Almirall’s aclidinium bromide/formoterol combination
  •     Boehringer's Spiriva Respimat (tiotropium) mist inhaler in COPD
  •     In idiopathic pulmonary fibrosis (IPF), Novartis’ QAX576, an anti-IL-13 in Phase II development, has been quietly terminated
  •     In asthma, GlaxoSmithKline and partner Theravance are still considering their strategy to progress Breo Ellipta (fluticasone furoate/vilanterol) for US approval.
  •     In pulmonary arterial hypertension (PAH), Actelion will need to get experts engaged in the discussion on Opsumit’s (macitentan) EU pricing. EU approval decision is expected YE.
  •     Bayer is in the planning stages of a Phase IIIb study (RESPITE) evaluating riociguat in PAH for those patients insufficiently treated with phosphodiesterase-5 inhibitors.
  •     PTC Therapeutics' ataluren for cystic fibrosis caused by nonsense mutations (nmCF).

Subscribers to BioPharm Insight received the Respiratory Report on October 15.

Non-subscribers, download the report.

About BioPharm Insight

BioPharm Insight is part of Infinata, a Financial Times Group company, and a leading provider of business intelligence solutions which also include BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.

About Infinata, Inc.

Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Business Inquiries: Holly Burke, hburke[at]infinata[dot]com, 781-619-0131
Media Inquiries: Brenda Nashawaty, Brenda[at]nashawaty[dot]com, 617-688-3253

Read the full story at http://www.prweb.com/releases/2013/11/prweb11300052.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. BioPharm Systems Named to the 2012 Lead411 Technology 200 List
2. BioPharm Systems to Host Webinar on Using iHelp in Oracle’s Siebel Clinical Trial Management System
3. BioPharm Systems to Host Webinar on Clinical Trial Supply Management with Siebel CTMS
4. Nine Lives Media Names BioPharm Systems to the MSPmentor 501
5. BioPharm Systems Unveils Study Data Mapper to Simplify the Preparation and Reporting of Clinical Data
6. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at ReportsnReports.com
7. Therapure Biopharma Inc. Awarded US Government Contract for Development of Anti-Nerve Gas Agent
8. World Antibiotic Resistance Market Saw Big Changes in Last Five Years, According to Biopharm Reports Study Available at MarketPublishers.com
9. Mass Spectrometry Marketplace Discussed by Biopharm Reports in In-demand Research Study Available at MarketPublishers.com
10. Study says children exposed to tobacco smoke face long-term respiratory problems
11. Study shows antibiotic improves respiratory function in lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... CONTACT:, Glenn ... Beverly Hills plastic surgeon Dr. Glenn Vallecillos experiments SculpSure, the hot, ... "Traditionally, plastic surgery has been centered around that idea that to achieve ones ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a comprehensive family ... Brian Seese leads the practice as a skilled and highly credentialed dentist who is ... Seese serves patients of all ages with excellence in general, restorative, and cosmetic ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of the ... 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs ... across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... -- Quest Diagnostics (NYSE: DGX ), the ... that it has been named one of the "World,s ... The annual survey designated Quest Diagnostics as one ... and Other Services" industry to attain Most Admired status, ... the designation. This is the second consecutive year Quest ...
(Date:2/16/2017)...  Newly published research from the CVS Health (NYSE: ... a private retailer can play in restricting access to ... today in the American Journal of Public Health ... from all CVS Pharmacy stores reduced the number of ... greater impact on those who bought cigarettes exclusively at ...
(Date:2/16/2017)... SCOTTSDALE, Ariz. , Feb. 16, 2017 /PRNewswire/ ... Exchange (HIE), announced today it is partnering with Orion Health ... contains 98% of all Maine residents, ... hospitals and over 500 ambulatory care sites. ... plans to deploy Orion Health,s Amadeus , a precision ...
Breaking Medicine Technology: